STAT+: California judge deals GSK a setback as first Zantac lawsuit will now go to trial
In a setback to GSK, a California judge ruled that a consumer cleared a key…
Category: Pharmaceuticals
STAT+: J&J loses a patent battle in India over a crucial tuberculosis drug
In a defeat for Johnson & Johnson, the Indian patent office has rejected its bid…
STAT+: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines
In the face of rising drug prices, health plan sponsors have quietly used a clever,…
STAT+: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
WASHINGTON — The future of Alzheimer’s treatments and coverage hung heavily over lawmakers’ Wednesday hearing…
STAT+: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Pills, patches, implants, and injections — the various forms of hormonal birth control have different…
STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
More than 200 civil society and patient advocacy groups are urging the U.K. government to…
STAT+: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
A new obesity treatment being developed by Altimmune met goals for weight loss in a…
STAT+: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
WASHINGTON — Moderna CEO Stéphane Bancel has some explaining to do. Bancel will appear alone…
Arizona plans to dramatically increase hepatitis C testing and treatment in prisons
WASHINGTON — The Arizona Department of Corrections is promising a federal judge that it will…
‘That scares me’: New childhood obesity guidelines still face a long road to consensus
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%
Following the lead of its rivals, Sanofi will cut the price of its most widely…
STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers
U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over…
STAT+: Califf criticizes insurers for doing too little on drug research
WASHINGTON — FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval…
STAT+: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug
In a rare move, a U.K. pharmaceutical industry trade group suspended Novo Nordisk for two…
STAT+: Medicare explains how it will choose drugs for negotiation
WASHINGTON — Medicare laid out Thursday in the greatest detail yet how it will choose…
Conservative Texas judge weighs challenge to abortion pill
AMARILLO, Texas — A conservative federal judge in Texas heard arguments Wednesday from a Christian group…
STAT+: Democratic lawmakers press pharmacy chains on abortion pill access
More than a dozen Democratic lawmakers are urging some of the nation’s largest drugstore chains…
.jpg)
STAT+: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Sanofi said Monday that it is acquiring Provention Bio, makers of a diabetes treatment, for…
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43…
Covering new weight loss drugs could strain Medicare, policy experts warn
The emergence of highly effective obesity drugs has spurred renewed efforts to get Medicare to…
STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap
And so, another working week will soon draw to a close. Not a moment too…
Opinion: Clearing the patent thicket: A pathway to faster generic drug approvals
Revelations that AbbVie, the manufacturer of Humira, made more than $100 billion in extra profits…
STAT+: An unlikely new 340B alliance emerges between PhRMA and community health centers
WASHINGTON — An unusual new alliance of the brand-drug lobby PhRMA and community health centers…
Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz ahead of midterm elections
WASHINGTON — Pfizer CEO Albert Bourla made the maximum possible campaign contribution to Mehmet Oz…
‘Truth is losing the battle’: FDA commissioner on grappling with a wave of health misinformation
The Food and Drug Administration is considering whether it needs to revamp guidance on how…
STAT+: Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA
After months of anticipation, the manufacturer of a controversial drug for premature births has agreed…
STAT+: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment
A Turkish court overturned a decision by the national antitrust regulator that two years ago…
STAT+: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
Vertex Pharmaceuticals revolutionized the treatment of cystic fibrosis. It also has unfinished business. The Boston…
STAT+: Teva quits brand lobby PhRMA, in line to lead generic lobby AAM
WASHINGTON — Teva Pharmaceuticals has quit the Pharmaceutical Research and Manufacturers of America, STAT has…
Opinion: Generics: a missing piece in China’s Covid-19 crisis response
China’s massive Covid-19 crisis, sparked in part by the country’s rolling back its strict zero-Covid…
STAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its…
STAT+: Pharma wins a key round in a court battle with hospitals over a drug discount program
In a victory for the pharmaceutical industry, a federal appeals court ruled drug companies have…
STAT+: ‘A classic case’: A legal expert on why lawsuits challenging abortion pill restrictions may succeed
A pair of lawsuits was filed last week challenging restrictions on access to abortion pills…
Opinion: As it turns 40, the Orphan Drug Act for rare diseases needs a refresh
This month marks the 40th anniversary of the Orphan Drug Act. Since it was signed…
STAT+: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients
After months of anticipation, the first biosimilar version of Humira will become available next week…
STAT+: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is…
FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy
The evolution of the coronavirus has knocked out another treatment. The Food and Drug Administration…
Opinion: A dangerous loophole for drug ads needs to be closed
A loophole in prescription drug regulation exposes American consumers to false and misleading claims of…
Watch: How do the new obesity drugs work?
Drugs like Wegovy and Ozempic are rapidly growing in popularity as weight-loss treatments. These medications…
STAT+: Novartis and Lilly turn to nonprofit, instead of FDA, to resolve dispute over drug ad
In a rare move, the Better Business Bureau National Programs settled a dispute between two…
Opinion: Making naloxone available over the counter won’t solve the overdose crisis — but it will help
The Food and Drug Administration aims to conduct priority reviews of at least two product…
STAT+: The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals
WASHINGTON — Congress just boosted the FDA’s authority over the post-market clinical trials that are…
The drug was meant to save children’s lives. Instead, they’re dying
Emily was combing her baby daughter’s hair when she first felt the lumps. It was…
STAT+: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad
A physicians’ group has filed a complaint with the U.S. Food and Drug Administration alleging…
STAT+: Amazon Pharmacy expands with new $5 monthly prescription service
Amazon is launching a new prescription service that lets patients on Amazon Prime get eligible…
STAT+: Many pediatric drug study results were never posted to a U.S. government database
Amid ongoing controversy over clinical trial transparency, a new analysis found that results of 43…
STAT+: Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates
WASHINGTON — Health care groups and their lobbyists spent big in the last few months…
STAT+: PhRMA terminates lobbying contract with White House official’s brother
WASHINGTON — The pharmaceutical industry lobbying group PhRMA has severed its contract with a lobbyist who…